glp-1 drugs for type 2 diabetes Clinical Focus on Agonists in Mellitus Lilly's Oral GLP-1 Foundayo Outperforms
Description
(2025, September 11)
17-19 The CAROLINA and CARMELINA studies of linagliptin demonstrated CV safety, but results have not yet been made available (Clinicaltrials.gov identifiers: NCT01243424 and NCT01897532)
Antagonistic hallmarks, which reflect the cellular responses to this damage
Pros and Cons of Oral vs Injectable GLP-1s VI
